John M.L. Ebos

5.5k total citations · 2 hit papers
49 papers, 4.1k citations indexed

About

John M.L. Ebos is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, John M.L. Ebos has authored 49 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 25 papers in Oncology and 20 papers in Cancer Research. Recurrent topics in John M.L. Ebos's work include Angiogenesis and VEGF in Cancer (18 papers), Renal cell carcinoma treatment (9 papers) and Cancer Cells and Metastasis (8 papers). John M.L. Ebos is often cited by papers focused on Angiogenesis and VEGF in Cancer (18 papers), Renal cell carcinoma treatment (9 papers) and Cancer Cells and Metastasis (8 papers). John M.L. Ebos collaborates with scholars based in United States, Canada and France. John M.L. Ebos's co-authors include Robert S. Kerbel, Christina R. Lee, James G. Christensen, William Cruz‐Muñoz, Georg A. Bjarnason, Amanda Tracz, Sébastien Benzekry, Anthony J. Mutsaers, Afshin Beheshti and Clare Lamont and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Medicine.

In The Last Decade

John M.L. Ebos

45 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

2009 1.4k citations John M.L. Ebos, Christina R. Lee et al. Cancer Cell profile →
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis

2011 548 citations John M.L. Ebos, Robert S. Kerbel Nature Reviews Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John M.L. Ebos United States	23	2.3k	1.6k	1.5k	711	411	49	4.1k
Andrew R. Reynolds United Kingdom	31	2.8k 1.2×	1.2k 0.7×	1.2k 0.8×	641 0.9×	440 1.1×	36	4.2k
Ibiayi Dagogo‐Jack United States	24	2.0k 0.8×	2.0k 1.2×	1.3k 0.9×	1.9k 2.6×	352 0.9×	85	4.5k
Marco Gerlinger United Kingdom	22	1.1k 0.5×	955 0.6×	1.2k 0.8×	647 0.9×	233 0.6×	62	2.4k
Oddbjørn Straume Norway	31	2.8k 1.2×	2.4k 1.4×	1.3k 0.8×	694 1.0×	495 1.2×	69	4.6k
Charlotte K.Y. Ng Switzerland	42	2.4k 1.0×	2.6k 1.6×	3.5k 2.3×	1.5k 2.1×	367 0.9×	120	6.5k
Paolo Michieli Italy	28	2.7k 1.1×	1.8k 1.1×	1.1k 0.7×	503 0.7×	355 0.9×	41	4.6k
Colin D. Weekes United States	28	1.4k 0.6×	2.1k 1.3×	758 0.5×	634 0.9×	379 0.9×	144	3.5k
Anne T. Collins United Kingdom	32	2.9k 1.2×	3.6k 2.2×	1.6k 1.0×	2.0k 2.8×	645 1.6×	71	6.0k
Marnix Jansen United Kingdom	31	1.5k 0.6×	1.8k 1.1×	1.1k 0.7×	992 1.4×	275 0.7×	82	4.2k
Patrizia Mancuso Italy	33	2.6k 1.1×	2.3k 1.4×	1.5k 1.0×	618 0.9×	682 1.7×	80	4.4k

Countries citing papers authored by John M.L. Ebos

Since Specialization

Citations

This map shows the geographic impact of John M.L. Ebos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John M.L. Ebos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John M.L. Ebos more than expected).

Fields of papers citing papers by John M.L. Ebos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John M.L. Ebos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John M.L. Ebos. The network helps show where John M.L. Ebos may publish in the future.

Co-authorship network of co-authors of John M.L. Ebos

This figure shows the co-authorship network connecting the top 25 collaborators of John M.L. Ebos. A scholar is included among the top collaborators of John M.L. Ebos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John M.L. Ebos. John M.L. Ebos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Benzekry, Sébastien, Michalis Mastri, Chiara Nicolò, & John M.L. Ebos. (2024). Machine-learning and mechanistic modeling of metastatic breast cancer after neoadjuvant treatment. PLoS Computational Biology. 20(5). e1012088–e1012088. 6 indexed citations

Shi, Yuhao, Melissa Dolan, Michalis Mastri, et al.. (2024). Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors. EMBO Reports. 26(2). 521–559. 1 indexed citations

Dolan, Melissa, Michalis Mastri, Mark D. Long, et al.. (2024). A Senescence-Mimicking (Senomimetic) VEGFR TKI Side Effect Primes Tumor Immune Responses via IFN/STING Signaling. Molecular Cancer Therapeutics. 23(9). 1241–1260. 2 indexed citations

Mohammadpour, Hemn, Minhyung Kim, Spencer R. Rosario, et al.. (2024). Downregulation of IRF8 in alveolar macrophages by G-CSF promotes metastatic tumor progression. iScience. 27(3). 109187–109187. 2 indexed citations

He, Xuedan, Melissa Dolan, Yuhao Shi, et al.. (2021). Immunization with short peptide particles reveals a functional CD8⁺ T-cell neoepitope in a murine renal carcinoma model. Journal for ImmunoTherapy of Cancer. 9(12). e003101–e003101. 20 indexed citations

Mastri, Michalis, Christina R. Lee, Amanda Tracz, et al.. (2018). Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors. Molecular Cancer Therapeutics. 17(7). 1602–1612. 5 indexed citations

Mastri, Michalis, Amanda Tracz, Christina R. Lee, et al.. (2018). A Transient Pseudosenescent Secretome Promotes Tumor Growth after Antiangiogenic Therapy Withdrawal. Cell Reports. 25(13). 3706–3720.e8. 21 indexed citations

Mastri, Michalis, et al.. (2016). The Challenges of Modeling Drug Resistance to Antiangiogenic Therapy. Current Drug Targets. 17(15). 1747–1754. 7 indexed citations

Francisco, Ignacio F. San, Viviana P. Montecinos, Paula Sotomayor, et al.. (2016). Androgens modulate male-derived endothelial cell homeostasis using androgen receptor-dependent and receptor-independent mechanisms. Angiogenesis. 20(1). 25–38. 29 indexed citations

10.

Benzekry, Sébastien, et al.. (2015). Modeling Spontaneous Metastasis following Surgery: An In Vivo-In Silico Approach. Cancer Research. 76(3). 535–547. 48 indexed citations

11.

Benzekry, Sébastien, Clare Lamont, Afshin Beheshti, et al.. (2014). Classical Mathematical Models for Description and Prediction of Experimental Tumor Growth. PLoS Computational Biology. 10(8). e1003800–e1003800. 364 indexed citations

12.

Tracz, Amanda, Michalis Mastri, Christina R. Lee, Роберто Пили, & John M.L. Ebos. (2014). Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy. Journal of Visualized Experiments. 19 indexed citations

13.

Mittal, Kriti, John M.L. Ebos, & Brian I. Rini. (2014). Angiogenesis and the Tumor Microenvironment: Vascular Endothelial Growth Factor and Beyond. Seminars in Oncology. 41(2). 235–251. 116 indexed citations

14.

Ebos, John M.L., Michalis Mastri, Christina R. Lee, et al.. (2014). Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy. EMBO Molecular Medicine. 6(12). 1561–1576. 33 indexed citations

15.

Kerbel, Robert S., Éric Guérin, Giulio Francia, et al.. (2013). Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis. The Breast. 22. S57–S65. 30 indexed citations

16.

Ebos, John M.L. & Роберто Пили. (2012). Mind the Gap: Potential for Rebounds during Antiangiogenic Treatment Breaks. Clinical Cancer Research. 18(14). 3719–3721. 10 indexed citations

17.

Ebos, John M.L. & Robert S. Kerbel. (2011). Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nature Reviews Clinical Oncology. 8(4). 210–221. 548 indexed citations breakdown →

18.

Kerbel, Robert S. & John M.L. Ebos. (2010). Peering into the aftermath: The inhospitable host?. Nature Medicine. 16(10). 1084–1085. 19 indexed citations

19.

Ebos, John M.L., Christina R. Lee, William Cruz‐Muñoz, et al.. (2009). Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis. Cancer Cell. 15(3). 232–239. 1383 indexed citations breakdown →

20.

Ebos, John M.L., Christina R. Lee, Elena Bogdanovic, et al.. (2008). Vascular Endothelial Growth Factor–Mediated Decrease in Plasma Soluble Vascular Endothelial Growth Factor Receptor-2 Levels as a Surrogate Biomarker for Tumor Growth. Cancer Research. 68(2). 521–529. 95 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact